Translating glutamate: from pathophysiology to treatment.
about
Auditory dysfunction in schizophrenia: integrating clinical and basic features.Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signalingThe cytokine model of schizophrenia: emerging therapeutic strategiesTargeting the glutamatergic system to treat major depressive disorder: rationale and progress to dateDeveloping Medications Targeting Glutamatergic Dysfunction in Autism: Progress to DateIndependent and additive effects of glutamic acid and methionine on yeast longevityHas an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophreniaNeural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia.Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.Reduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system xc⁻ activity in the medial prefrontal cortex.Convergent findings for abnormalities of the NF-κB signaling pathway in schizophrenia.Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics.Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.Inhibition of STEP61 ameliorates deficits in mouse and hiPSC-based schizophrenia models.Electrophysiological intermediate biomarkers for oxidative stress in schizophreniaReduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome.Intracranial self-stimulation to evaluate abuse potential of drugs.Electrical synapses and their functional interactions with chemical synapses.Neuroprotective effect of penehyclidine hydrochloride on focal cerebral ischemia-reperfusion injury.Hampered long-term depression and thin spine loss in the nucleus accumbens of ethanol-dependent ratsFuture directions for research in autism spectrum disorders.Transcranial magnetic stimulation in the treatment of substance addictionBehavioral assessment of acute inhibition of system xc (-) in ratsMultimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats.Group II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons.A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophreniaEffects of (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline on glutamate transporter 1 and cysteine/glutamate exchanger as well as ethanol drinking behavior in male, alcohol-preferring rats.Genome-wide gene pathway analysis of psychotic illness symptom dimensions based on a new schizophrenia-specific model of the OPCRITThe N-methyl-D-aspartate receptor as a neurobiological intersection between bipolar disorder and alcohol use: a longitudinal mismatch negativity studyR-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.Chronic Cigarette Smoking in Healthy Middle-Aged Individuals Is Associated With Decreased Regional Brain N-acetylaspartate and Glutamate Levels.Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence.Variable prenatal stress results in impairments of sustained attention and inhibitory response control in a 5-choice serial reaction time task in rats.Molecular cause and functional impact of altered synaptic lipid signaling due to a prg-1 gene SNPDifferential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy.Pituitary Adenylate cyclase-activating polypeptide orchestrates neuronal regulation of the astrocytic glutamate-releasing mechanism system xc (.).Posteromedial cortex glutamate and GABA predict intrinsic functional connectivity of the default mode network
P2860
Q26796401-D4237152-F9A5-44CC-837D-A84444B2E495Q26830533-115E0A51-1AC8-446A-A50B-6F72C47DCB7DQ26864995-44EA6B0B-F788-4619-BA6A-52E886B3B740Q26865996-73737B77-4090-4EA0-99C4-DC60CC902F16Q27004490-2629F1D9-89C7-4FEB-8442-6D89348C8445Q27025683-10109C44-341A-4552-ABEA-1C2275E021E1Q27937541-7EBDAF53-E4B9-46F3-B374-059BACE2F85BQ28275290-E8FF2C4F-CF07-43C8-BE92-F09211F508A5Q30384219-55894735-ECC9-4C48-AF59-5902D5AA17E0Q30384452-09E58F27-1F18-43CD-8A8B-F093D4B839D4Q30440988-31DE27E4-9EE0-4E29-80FA-656CD7CB3FFDQ30443697-5A11A527-BFAC-48E9-960E-7706AEFC75AEQ30564474-F14001D4-58BF-4DB7-8971-7D0C287FCDDDQ30685335-B2D22034-32F2-4954-B844-D05375EBC6CBQ30732395-00F6D7C6-6C48-414F-8C82-593BF7CD5E81Q33574936-41676767-054E-46D3-9F6D-70F6DCFA5466Q33647885-A88A7874-FD21-4CA8-AFBD-CC1315DD6FA3Q33775794-452C8B29-B278-46C0-B60D-E13AC3213C27Q33845750-23DBD71E-AA99-43AC-B1A0-EA13C4BE197EQ33881841-6DC8BD37-026B-46BB-ACEF-98AECC4649E6Q34094903-32535BAB-3CC6-4E94-8183-02FCACB2E5C6Q34144592-05378853-3648-4EEE-A004-02E25C592051Q34180429-BB85436A-64A1-4F48-B3B5-59E32FE571ABQ34388951-11DB75AB-0C9E-4893-8D31-3B752D6574C6Q34420036-A4042FAD-F343-48B0-A557-746B9072E13CQ34559591-82EA3E60-12B5-4679-975D-8AB471971F9EQ34675038-901C5D7C-28F0-4E9A-9204-63221A31BB67Q34770351-0209301B-19C8-41EC-B9A3-0B057FD3CA34Q35417634-BB99028B-F92D-4AE1-8F70-B93519D54981Q35537274-93E11182-0C04-4F7A-8144-38C0696F91C2Q35626959-FF416A5F-2105-4E60-AEDB-740C51B4972AQ36077206-0D412CD4-A4C7-4445-BEF1-EAE1E453DE77Q36143156-548E8E30-7416-4010-9768-E58828C66CE3Q36189837-24FEB0AF-F9F0-4767-9C62-9DB9DAFC2958Q36234288-795095D1-3868-474A-A22E-80D730433F29Q36448887-898BEEF6-66D2-4319-AC4F-413CA446E676Q36477821-5FDDA0E5-BDA8-46CD-BDA0-E7AC2CA09F66Q36798980-E08B3400-6584-451E-82A4-C45D438F6BEBQ36930072-00CAA042-F36B-4C89-965D-338703911DA7Q37241069-AF55719A-D98E-4C14-B325-5AB6CB4AB5C7
P2860
Translating glutamate: from pathophysiology to treatment.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Translating glutamate: from pathophysiology to treatment.
@ast
Translating glutamate: from pathophysiology to treatment.
@en
type
label
Translating glutamate: from pathophysiology to treatment.
@ast
Translating glutamate: from pathophysiology to treatment.
@en
prefLabel
Translating glutamate: from pathophysiology to treatment.
@ast
Translating glutamate: from pathophysiology to treatment.
@en
P2093
P2860
P1476
Translating glutamate: from pathophysiology to treatment.
@en
P2093
Carlos Zarate
Chi-Ming Lee
Daniel Umbricht
Darryle Schoepp
Kalpana Merchant
Mark F Bear
Mihaly Hajos
Nora D Volkow
Peter W Kalivas
William Z Potter
P2860
P304
P356
10.1126/SCITRANSLMED.3002804
P407
P577
2011-09-01T00:00:00Z